AU2002214583A1 - Pharmaceutical applications of hydrotropic agents, polymers thereof, and hydrogels thereof - Google Patents

Pharmaceutical applications of hydrotropic agents, polymers thereof, and hydrogels thereof

Info

Publication number
AU2002214583A1
AU2002214583A1 AU2002214583A AU1458302A AU2002214583A1 AU 2002214583 A1 AU2002214583 A1 AU 2002214583A1 AU 2002214583 A AU2002214583 A AU 2002214583A AU 1458302 A AU1458302 A AU 1458302A AU 2002214583 A1 AU2002214583 A1 AU 2002214583A1
Authority
AU
Australia
Prior art keywords
hydrogels
polymers
pharmaceutical applications
hydrotropic agents
hydrotropic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002214583A
Inventor
Ghanashyam Acharya
Jaehwi Lee
Sang Cheon Lee
Kinam Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of AU2002214583A1 publication Critical patent/AU2002214583A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
AU2002214583A 2000-10-11 2001-10-11 Pharmaceutical applications of hydrotropic agents, polymers thereof, and hydrogels thereof Abandoned AU2002214583A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23945500P 2000-10-11 2000-10-11
US60/239,455 2000-10-11
US29495701P 2001-05-31 2001-05-31
US60/294,957 2001-05-31
PCT/US2001/032064 WO2002030466A2 (en) 2000-10-11 2001-10-11 Pharmaceutical applications of hydrotropic agents, polymers thereof, and hydrogels thereof

Publications (1)

Publication Number Publication Date
AU2002214583A1 true AU2002214583A1 (en) 2002-04-22

Family

ID=26932588

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002214583A Abandoned AU2002214583A1 (en) 2000-10-11 2001-10-11 Pharmaceutical applications of hydrotropic agents, polymers thereof, and hydrogels thereof

Country Status (3)

Country Link
US (1) US20030031715A1 (en)
AU (1) AU2002214583A1 (en)
WO (1) WO2002030466A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040185101A1 (en) * 2001-03-27 2004-09-23 Macromed, Incorporated. Biodegradable triblock copolymers as solubilizing agents for drugs and method of use thereof
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
KR100508518B1 (en) * 2002-11-13 2005-08-17 한미약품 주식회사 Method for the preparation of paclitaxel solid dispersion by using the supercritical fluid process and paclitaxel solid dispersion prepared thereby
US20040197408A1 (en) * 2002-12-30 2004-10-07 Angiotech International Ag Amino acids in micelle preparation
US7045559B2 (en) * 2003-12-18 2006-05-16 Kimberly-Clark Worldwide, Inc. Electrically conductive adhesive hydrogels with solubilizer
US20050136023A1 (en) * 2003-12-18 2005-06-23 Kimberly-Clark Worldwide, Inc. Electrically conductive adhesive hydrogels with a thermally activated chemical initiator
KR20080003322A (en) * 2005-02-24 2008-01-07 엘란 파마 인터내셔널 리미티드 Nanoparticulate formulations of docetaxel and analogues thereof
MX2008014953A (en) * 2006-05-26 2009-03-05 Bayer Healthcare Llc Drug combinations with substituted diaryl ureas for the treatment of cancer.
US7816412B2 (en) * 2007-02-23 2010-10-19 Conmed Corporation Electrically conductive hydrogels
US7537532B2 (en) * 2007-05-16 2009-05-26 Young Carl D Handle for implement and method
US20110183980A1 (en) * 2009-09-21 2011-07-28 Conn P Jeffrey O-benzyl nicotinamide analogs as mglur5 positive allosteric modulators
US20120289553A1 (en) * 2009-12-28 2012-11-15 Laboratorio Reig Jofre, S.A. Oral liquid pharmaceutical composition of nifedipine
US9018177B2 (en) 2012-10-12 2015-04-28 L'oreal S.A. Cosmetic compositions for increasing bioavailability of the active compounds baicalin and/or vitamin C
US9107853B2 (en) 2012-10-12 2015-08-18 L'oreal S.A. Compositions containing phenolic compounds and hydrotropes for cosmetic use
US9023826B2 (en) 2012-10-12 2015-05-05 L'oreal S.A. Compositions containing adenosine and the hydrotropes caffeine and nicotinamide for cosmetic use
US9072919B2 (en) 2012-10-12 2015-07-07 L'oreal S.A. Synergistic antioxidant cosmetic compositions containing at least one of baicalin and taxifolin, at least one of caffeine and nicotinamide, at least one of vitamin C and resveratrol and ferulic acid
US9669242B2 (en) * 2013-07-01 2017-06-06 L'oreal Compositions containing at least two phenolic compounds, a lipid-soluble antioxidant and at least one hydrotrope for cosmetic use
US10561766B2 (en) * 2015-09-15 2020-02-18 W. L. Gore & Associates, Inc. Drug composition and coating
CA3000428C (en) * 2015-10-02 2023-12-12 Purdue Research Foundation Hydrophobic highly branched carbohydrate polymers
EP3505154B1 (en) * 2017-12-26 2022-04-06 Industrial Technology Research Institute Composition for improving the solubility of poorly soluble substances, use thereof and complex formulation containing thereof
WO2022075470A1 (en) * 2020-10-09 2022-04-14 国立大学法人 東京大学 Nicotinamide-encapsulating micelles, and pregnancy-induced hypertension syndrome therapy composition containing nicotinamide-encapsulating micelles

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756450A (en) * 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
US4946967A (en) * 1988-11-03 1990-08-07 Gaf Chemicals Corporation Polymerizable derivatives of 5-oxo-pyrrolidinecarboxylic acid
US4987210A (en) * 1988-11-03 1991-01-22 Gaf Chemicals Corporation Polymerizable derivatives of 5-oxo-pyrrolidinecarboxylic acid
US5008367A (en) * 1989-05-08 1991-04-16 Gaf Chemicals Corporation Poly(pyrrolidonyl oxazoline)
US4981974A (en) * 1989-05-08 1991-01-01 Gaf Chemicals Corporation Polymerizable pyrrolidonyl oxazoline monomers
US4933463A (en) * 1989-05-08 1990-06-12 Gaf Chemicals Corporation Polymerizable pyrrolidonyl oxazoline monomers, homopolymers and copolymers
DE4221880A1 (en) * 1992-07-03 1994-01-05 Alfatec Pharma Gmbh Solid and liquid solutions of poorly water-soluble drugs
DE69632401T2 (en) * 1995-06-07 2005-05-19 Imarx Pharmaceutical Corp., Tucson NEW TARGETED MEANS FOR DIAGNOSTIC AND THERAPEUTIC USE
US5693320A (en) * 1996-03-17 1997-12-02 Ube Industries, Ltd. (Meth)acryloyloxy substituted acetylsalicylates and polymers thereof
EP0910351A1 (en) * 1996-06-27 1999-04-28 G.D. Searle & Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
CA2282439C (en) * 1997-03-05 2010-05-04 Sugen, Inc. Formulations for hydrophobic pharmaceutical agents
KR100436059B1 (en) * 1997-12-30 2004-12-17 주식회사 하이닉스반도체 Method for forming ferroelectric capacitor to prevent ferroelectric characteristic of pzt tnin film from being deteriorated
US6287588B1 (en) * 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof

Also Published As

Publication number Publication date
US20030031715A1 (en) 2003-02-13
WO2002030466A3 (en) 2002-08-08
WO2002030466A2 (en) 2002-04-18

Similar Documents

Publication Publication Date Title
AU2002214583A1 (en) Pharmaceutical applications of hydrotropic agents, polymers thereof, and hydrogels thereof
AU2002338952A1 (en) New 3,4-alkylenedioxythiophene compounds and polymers thereof
AU3177700A (en) Polymers, their preparation and uses
EP1247815A3 (en) Modified oligonucleotides and uses thereof
AU2001251742A1 (en) Lenses and uses, including microscopes
AU2002315389A1 (en) Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
AU2002329873A1 (en) Halogenated calixpyrroles, calixpyridinopyrroles and calixpyridines, and uses thereof
AU2001292336A1 (en) Monomer, polymer, and ocular lens comprising the same
AU2001279288A1 (en) Drug diffusion coatings, applications and methods
AU2001235773A1 (en) Electro-luminiscent polymers, their preparation and uses
AU2001269961A1 (en) Improved polymers and polymerization processes
AU2001285810A1 (en) High functional polymers
AU2001249871A1 (en) Ether-amine based polymerization catalysts, compositions and processes using same
GB2353526B (en) Novel photoresist monomers,polymers thereof,and photoresist compositions containing the same
AU2002241762A1 (en) Polymerization process
AUPR218000A0 (en) Polymer gels and their preparation
AU3930200A (en) Film forming polymers, methods of use, and devices and applications thereof
AU2002354070A1 (en) Medical polymers and use thereof
AU2002255598A1 (en) Polymers and photoresist compositions
AU2002255786A1 (en) Novel polymers and photoresist compositions comprising same
AU5589499A (en) Water-soluble, hydrolytic-stable amphoteric monomer and polymers therefrom
AU2002246541A1 (en) Rna polymers and uses thereof
AU2001285901A1 (en) High functional polymers
AU2002246057A1 (en) Thermoplastic halogenated polymer compositions, method for preparing same and use thereof
AU2002328423A1 (en) Composition, amphoteric polymeric flocculant and use of both